anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The present invention relates to a preparation capable of promoting growth and intelligence development for teenagers and children as well as a preparing method thereof. The preparation is formed from preparation of L-lysine hydrochloride, taurine, biologic calcium carbonate, zinc gluconate, bitter cardamon, chicken&#39;s gizzard-membrane, citron and oyster. The preparing method has a process flow that the processed qualified bitter cardamon, the chicken&#39;s gizzard-membrane, and the citron and the oyster are added with water, and are heated for decoction and filtered. The decoction liquid is stood, filtered, deslagged, and is cooled and concentrated to extractum, and the extractum is dried and disinfected to obtain extract. The extract and the added L-lysine hydrochloride, the taurine, etc. are pulverized, and sieved, and is mixed in a mixing machine for preparing particles. The particles are dried and disinfected in 80 DEG C, and product is obtained through size stabilization, pelleting and subpackaging. The preparation has the functions of increase of diet, spirit activity, flushing complexion flushing, reinforcement of memory and undisturbed sleep. The preparation can also be used for promoting growth in stature, body weight and increase of haemoglobin, and promoting growth of children and intelligence development, and the prescription has no side effect.
PURPOSE:To obtain a stable liposome capable of favorably controlling directivity to a target organ by blending a synthetic lipid with a medicine and further, as necessary, blending phospholipid therewith. CONSTITUTION:A synthetic lipid expressed by the formula [R is methyl or carboxymethyl; X is the formula N&lt;+&gt;(CH3)3.Br&lt;-&gt; or the formula SO3&lt;-&gt;.Na&lt;+&gt;;k is 1-10; m and n are 1-20] is blended with a medicine. Further, as necessary, a phosholipid (e.g. phosphatidyl-choline) is blended therewith. The blend amount of phospholipid is an amount of 0.1-50 pts.wt. based on 1 pts.wt. synthetic lipid. Stable liposome preparation containing a fat-soluble medicine and a water-soluble medicine is obtained by using the synthetic lipid of the formula and this liposome preparation exhibits internal kinetics different from well-known liposome and has high transition property to an organ such as heart organ and low transition property to the spleen.
The human male&#39;s ability to ejaculate is diminished by administering to the male a 0.06-0.725 g. dose of an acid-addn. salt of d- 1,3,4,9,10,10a-hexahydro-6-methoxy-11-methyl-2H, 10, 4a- iminoethanophenanthrene (I). Cpd. (I) is used as a birth control agent. The ability of a male to ejaculate can be delayed or even prevented for about 15 hours depending on the dose level. Also the amount of semen and living sperm ejaculated is greatly reduced, so minimising the possibility of fertilising the ovum. With increasing dosage of (I) there is also an increasing delay towards the point of ejaculation during physical stimulation, e.g. with 0.08-0 2g. the delay is from 15-30 mins. from initial stimulation.
Device (8.k), that communicates in both directions has purpose to enable ECG/EEG/Blood pressure/video conference interactive diagnostics. The mentioned communication in both directions comprise of one or more Medical Doctors (1.i) who are in charge of setting digital parameters that are used for control of diagnostic procedure (ECG/EEG/ Blood pressure/video conference) and control the examination of the patient (10.k), or a few of them. Communication device (2.i) with client program application connected via communication channel (34) to the computer (4). Computer (4) has a function of the host computer that does commutation, accepts digital parameters of diagnostic procedure. Mentioned digital parameters of diagnostic procedure are via communication channel (5.k) communicated to patients communication device (6.k) that has client program application. The patient&#39;s communication device (6.k) communicates with the device (8.k) via communication channel (7.k). Device (8.k) at the same time: a) exchanges and saves parameters for ECGIEEGI Blood pressure/video conference with communication device (6.k) of the patient (10.k); The parameters and information about the state of the device are communicated back to the Medical Doctor (1.i), b) according to defined digital parameters conducts diagnostic procedure linked by cables (9.k) applied on the patient (10.k) for ECG/EEG/Blood pressure; c) in accordance with defined digital parameters that are communicated to video conference equipment (on the position of the device 8.k), does diagnostic procedure of video examination of the patient (10.k); d) stored parameters we used oam and ly when the devices (8.k and 6.k) are operated in stand alone mode in absence of communication channel (5.k); Users interface on client program enable ample connedion to the web-agent application on the host compute (4). Web-agent application provides commutation that is a precondtion for the direct communication beween client and the server At the host computer (4) the web-agent application does access control, archive and compilation of the records and communicated data.
The invention belongs to the skin care product category of skin cleaning and maintenance, and is characterized by using a water soluble compound containing boron, iodine, bromine, selenium, potassium, sodium, chloride, zinc and other elements to prepare powder, and using 1000 times of water to dissolve the powder into high quality mineral water and sea water for washing the face or taking a shower. The product is based on the analysis of components of domestic and foreign high-quality mineral water and sea water, and uses research results of dermatology and cosmetology to achieve the purpose &#34;deriving from the nature but higher than the natural&#34;. People may not be restricted by time and place, and can enjoy achievements brought by scientific and technological progresses. The product can clear away dead skin and excess fat on skins, relax the muscles and stimulate the blood circulation, eliminate fatigue, strengthen brain and soothe the nerves, diminish inflammation and relieve itching, soften, tender and beauty the skins and the like, has certain effects on chronic dermatitis, arthritis, relieving muscle and nerve pains and the like. The product shows good effects by use of thousands of people. This product production has the advantages of low production cost and simple technology, and has the value of popularization.
PURPOSE:To obtain a double membrane lipid composition which enables the absorption of dolichol through the digestive tracts and the oral administration of dolichol, by dissolving a dolichol useful as a medicine such as a hematinic agent and a phospholipid at a specific ratio in an organic solvent, and mixing the solution in the presence of a specific amount of water. CONSTITUTION:The titled composition can be produced by dissolving (A) 8-40pts.wt. of the compound of formula I (the group of formula II is trans- isoprene unit; the group of formula III is cis-isoprene unit; n is integer of 12-18) or its ester (abbreviated as dolichol) and (B) 100pts. of the compound of formula IV (R&lt;1-2&gt; are 15-21C hydrocarbon group; X&lt;1&gt; is -CH2CH2N&lt;+&gt;H3, etc.) and/or formula V [X&lt;2&gt; is -CH2CH(OH)CH2OH, etc.] (abbreviated as phospholipid) in an organic solvent, distilling off the solvent, adding 500-100,000pts.wt. of water to the residue, and stirring the mixture. The absorption through the digestive tract and the oral administration are enabled by the proper selection of the weight ratio of dolichol to the phospholipid.
The present invention is a method and composition for treatment of ischemic, metabolic, congenital, or degenerative disorders of the central or peripheral nervous system. The composition is formed by encapsulation within an implantable biocompatible polymeric device of one or more compounds which have the effect or replacing or stimulating functions of the nervous system. A variety of biocompatible polymers including both biodegradable and non-degradable polymers can be used to form the implants. An essential feature of the composition is linear release, achieved through manipulation of the polymer composition and form. The selection of the shape, size, drug, polymer, and method for implantation are determined on an individual basis according to the disorder to be treated and the individual patient response. A plethora of neurally active substances can be used to treat or manipulate neurological disorders, including Parkinson&#39;s Disease, particularly the subset which is refractory or poorly responsive to existing therapies; Alzheimer&#39;s Disease; Huntington&#39;s Disease; and trauma, such as spinal cord injury.
1463327 Isolating conalbumin &amp;c. from biological materials OFFICINA TEREPEUTICA ITALIANA OTI LABORATORIO BIOLOGICO SpA 22 Oct 1974 [31 Oct 1973] 45750/74 Heading C3H A method of isolating a transferrine, particularly conalbumin, from biological material containing recoverable transferrine, involves passing the biological material in fluid condition at a pH between 3 and 6 through a solid carrier containing chelating groups coordinated to metal ions (iron, copper &amp;c.) in the presence of a buffer solution at a pH between 3 and 6 which is free of chelating properties, and then eluting the resulting transferrine-metal complex from the solid carrier and recovering pure transferrine in a conventional fashion. An acetate buffer solution of molarity between 0À01 and 0À2 M is used in adsorbing the transferrine on the carrier. For the elution of the transferrine complex produced, either a buffer solution having a pH between 6 and 11, or a buffer solution of pH between 3 and 6 containing chelating groups (sodium citrate) at a concentration of 10&lt;SP&gt;-3&lt;/SP&gt; M or higher, is suitable. The biological material is first deionized by treatment with a mixture of anionic and cationic resins. Compounds having chelating properties of M.W. lower than 10,000 i.e. lower than that of transferrine, may be removed by dialysis. The examples are directed to the isolation of conalbumin from egg white using a ferric-carboxymethyl cellulose carrier.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a plaster containing tulbuterol, exhibiting less change with the lapse of time in bonding physical properties such as a skin adhesiveness, etc., after pasting and enabling the constant release of a medicine for a long time and also a high percutaneous absorption even by using a small amount of the medicine to improve medicine utilization rate.  &lt;P&gt;SOLUTION: This plaster is provided by installing an adhesive layer on at least one side surface of a medicine-non-permeating supporting layer, and the adhesive layer is constituted of an acrylic adhesive composition constituted of 76-95 wt. % (meth)acrylic acid alkyl ester copolymer, ≥2.0 wt. % and &lt;5.0 wt. % tulbuterol, 2.0-30 wt. % at least ≥1 kind of a hydrophobic oil selected from the group consisting of squarane, isopropyl palmitate and liquid paraffine and 0-2.0 wt. % at least ≥1 kind of an acidic substance selected from the group consisting of lactic acid, acetic acid and a methacrylic acid copolymer. The (meth)acrylic acid alkyl ester is characterized by consisting of 75-85 wt. % 2-ethylhexyl methacrylate, 10-20 wt. % lauryl methacrylate and 5-15 wt. % 2-ethylhexyl acrylate.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a screening method for compounds promoting or inhibiting the activities of a new sodium dependant bile acid transporter protein, Na&lt;SP&gt;+&lt;/SP&gt;/H&lt;SP&gt;+&lt;/SP&gt;- exchanger protein, P type ATPase protein and vanilloid receptor protein, polynucleotides encoding these proteins, antisense polynucleotides for these polynucleotides and antibodies against these proteins, and compounds promoting or inhibiting the expression of the genes of these proteins, and compounds obtained by the screening method.  &lt;P&gt;SOLUTION: The proteins are useful as diagnostic markers for e.g. hypertension, arteriosclerosis, genetic or gastrointestinal diseases; respiratory diseases, renal diseases or gastrointestinal diseases; pancreatic diseases, central nervous system diseases, gastrointestinal diseases or respiratory diseases; inflammatory diseases, rheumatic diseases or diabetic neuropathy. The compounds promoting or inhibiting the activities of the proteins and obtained by the screening method by using the proteins can be used as e.g. the preventing and treating agents of the above diseases.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
PURPOSE:To industrially and advantageously obtain the subject compound useful as an antiulcer agent, etc., by reacting a specific compound with methoxyphenyl bromoacetate in a mixed solvent of a water-immiscible inert organic solvent and water in the presence of a phase-transfer catalyst and a base. CONSTITUTION:A compound expressed by formula I (either of R&lt;1&gt; and R&lt;2&gt; is methoxy and the other is H) or an acid addition salt thereof [e.g. 1-(2,3,4- trimethoxybenzyl)piperazine.dihydrochloride] is reacted with 4-methoxyphenyl bromoacetate in a mixed solvent of a water-immiscible inert organic solvent (e.g. toluene) and water in the presence of a phase-transfer catalyst (e.g. tetra-n- butylammonium bromide) and a base (e.g. potassium carbonate) to afford the objective compound expressed by formula II.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a fusion protein for use as a ligand-dependent transcription.  &lt;P&gt;SOLUTION: The fusion protein includes a nucleotide binding domain operatively linked to a modified ligand-binding domain derived from an intracellular receptor. The fusion protein includes a transcription regulating domain. The polynucleotide encodes the fusion protein. The expression vector and the transfected cells are provided. The nucleotide binding domain is a zinc-finger peptide that binds to a targeted contiguous nucleotide sequence of from 3 to 18 nucleotides. The fusion protein is used for gene therapy.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain a polyphenol composition maintaining its inherent physiological functions and improved in specific bitterness and astringency by including delipidated yolk. SOLUTION: The objective polyphenol composition is obtained by including delipidated yolk. The lipid content in the delipidated yolk is preferably &lt;=10 wt.%. The polyphenol is preferably (+)-catechin, (-)-epicatechin, (+)- gallocatechin, (-)-epigallocatechin, (-)-epicatechin gallate or (-)-epigallocatechin gallate. The containing ratio of the delipidated yolk is preferably 0.5-10 times based on the polyphenol. This composition is recovered by mixing the polyphenol with a solution or a suspension including delipidated yolk powder, sufficiently agitating the resultant and then filtrating, concentrating a solvent under reduced pressure or precipitating with a solvent (e.g. water or ethanol) or an acid (e.g. hydrochloric acid or sulfuric acid) or the like. The composition can be used together with vitamins, antibacterial and germicidal agents, coloring matters or the like.
PROBLEM TO BE SOLVED: To provide methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer&#39;s disease.SOLUTION: Antibodies or its active fragments comprise amino acid sequences, wherein the antibodies or its active fragments can specifically bind to β amyloid. The antibodies or its active fragments are produced by hybridoma cell lines. An isolated polynucleotide encodes the antibodies or its active fragments. A composition comprises the antibodies or its active fragments. A cell line is characterized in that it produces the antibodies or its active fragments. The antibodies are chimeric antibodies humanized with a monoclonal antibody.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a manufacturing method of a needle-like body capable of preferably making the needle-like body.  &lt;P&gt;SOLUTION: In the manufacturing method of the needle-like body, an original plate of the needle-like body is made, and a duplicate plate of the original plate of the needle-like body is made. Heat curing treatment using a thermosetting resin is used for making the duplicate plate wherein there is a difference between the temperatures of the sharp tip end part and the root part of the needle-like body. The thermosetting resin is known to show differences in thermal shrinkage depending on the heat curing treatment temperature when the temperature returns to an ambient temperature. According to the construction, since there is the difference between the temperatures of the sharp tip end part and the root part of the needle-like body, it is possible to conduct fine adjustment of the sharp tip end part and the root part of the needle-like body by using the amount of the thermal shrinkage.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To provide a preparative method for the subject oil-in-water type emulsion cosmetics capable of stably emulsifying a cationic surfactant which is liable to be hydrolyzed, and obtaining the cosmetics excellent in stability and performance by adding an oil phase containing a specific cationic surfactant and a higher alcohol to a water phase of a specific pH. SOLUTION: An oil phase comprising (A) a cationic surfactant expressed by formula (R1 is a 3-37C alkyl, alkenyl; X is -OCO-, -COO-, etc.; R2 is a 1-5C alkylene; R3-R5 are each a 1-4C alkyl, alkenyl, hydroxyalkyl; Y- is an anion) and (B) a higher alcohol (e.g. cetanol, etc.), is added to a water phase of pH &lt;=4. For example, 0.01-15 wt.% of the component A and 0.05-30% of the component B are formulated in the oil phase and the formulating ratio (weight ratio) is preferably set to the component A: the component B=10:1-1:10 and the mixing ratio (weight ratio) of the oil phase and the water phase is set to oil phase: water phase = 5:1-1:20.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition and method for treating or preventing hyperacute rejection.  &lt;P&gt;SOLUTION: The invention relates to mucin-immunoglobulin fusion polypeptides, methods for producing the same and methods for treating or preventing hyperacute rejection and more particularly the mucin part of the fusion polypeptides has been glycosylated by an alpha 1, 3-galactosyltransferase and a beta 1, 6 N-acetylglucosaminyltransferase. This is based on that carbohydrate epitope Galα1, 3Gal(αGal) may be specifically expressed in high density by different core sugar chains on the main chain of mucin type protein. Such the αGal epitope of high density causes increase of binding or removal (that is, adsorption) of anti-αGal compared with free sugars or brings about an αGal determinant combined with solid phase. Here, the polypeptide is called as αGal fusion polypeptide.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain a transparent gel composition, having transparency, excellent in touch feeling of use without causing the lowering of viscosity and having good effects on ultraviolet light absorptivity by compounding a specific water-soluble ultraviolet light absorber with a specified polymer in combination. SOLUTION: This transparent gel composition is obtained by compounding one or more of saccharide-based water-soluble ultraviolet light absorbers with a carboxyvinyl polymer in combination. A cinnamic acid derivative, a benzophenone derivative and a 1,3-propanedione derivative are cited as the saccharide-based water-soluble ultraviolet light absorbers. A compound, etc., represented by formula I (A is a residue after removing one OH from a saccharide; R is a hydrocarbon) or formula II [B is a residue after removing (n)×OHs from a saccharide or a sugaralcohol; X is an alkoxy; (a) is 1-3; (n) is an integer] are cited as the cinnamic acid derivative and a compound, etc., represented by formula III (R&lt;1&gt; and R&lt;2&gt; are each H or OH; R&lt;3&gt; to R&lt;10&gt; are each H, OH, etc.) are cited as the benzophenone derivative.  The amount of the compounded ultraviolet light absorbers is 0.01-20.0 wt.% and that of the carboxyvinyl polymer is 0.01-5.0 wt.%.
The present invention relates to an extract of Agarum clathratum subsp. yakishiriense Yamada ex G.H. Boo &amp; P.C. Silva, which is a seaweed, a fraction thereof, and an isolated compound thereof for treatment and prevention of hearing loss. The extract derived from Agarum clathratum subsp. yakishiriense Yamada ex G.H. Boo &amp; P.C. Silva, the fraction thereof, and monogalactosylmonoacylglycerol, which is an isolated compound thereof are derived from a natural product and are not toxic and safe to a human body. In addition, the extract, the fraction thereof, and the compound thereof of the present invention exhibit a protective effect on an auditory hair cell in various zebrafish animal models of hearing loss, and can be effectively applied to the prevention and treatment of hearing loss without a side effect.
NEW MATERIAL:Compounds expressed by formula I (R&lt;1&gt; is 4-20C straight-chain or branched chain alkyl; R&lt;2&gt; is H or protecting group of OH; R&lt;3&gt; is H or protecting group of COOH) and salt thereof. EXAMPLE:(+ or -)-tert-Butyl syn-2-fluoro-3-hydroxymyristate. USE:An aldose reductase inhibitor useful as a remedy for diabetic complications (e.g., cataract). PREPARATION:A compound expressed by formula II and a compound expressed by formula III are subjected to aldose condensation reaction according to the Welch and Seper method to provide a compound expressed by formula IV, which is then reacted with an alkaline earth metal monoperphthalate by the Baeyer-Villiger reaction to afford a compound expressed by formula V in the compounds expressed formula I. Furthermore, the carboxyl-protecting group, as desired, is removed or the hydroxyl group at the 3-position is protected with a protecting group. The carboxyl-protecting groups, as desired, is removed to provide compounds expressed by formulas VI-VIII in the compounds expressed by formula I.
PURPOSE:To prevent a soft capsule from mutually sticking even at high temperature and humidities, enhance sliding properties in compounding and packaging operations and improve operating efficiency by blending dietary fiber in a film of the soft capsule. CONSTITUTION:A capsule is obtained by blending &gt;=0.5wt.%, preferably 1-30wt.% dietary fiber or its derivative or its processed substance in a film of the soft capsule. The dietary fiber refers to hardly digestible ingredients which are not digested with human digestive enzymes in foods and agar, carrageenan, alginic acid, chitin, pectin, xanthan gum, lignin, etc., are cited. Calcium alginate, chitosan, hydroxypropyl starch, etc., are cited as their derivatives. A dietary fiber-containing processed food obtained by processing a dietary fiber-containing food or other raw materials by various methods, e.g. a processed food containing a homogeneous substance of cellulose, regenerated from an aqueous solution of an alkali metallic hydroxide and having crystal type of cellulose II and edible polysaccharides in an amount of &gt;=10% as a continuous substance is cited as the aforementioned processed substance.